PEAK BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0086 USD | 0.00% |
|
0.00% | -95.41% |
| 03-05 | Akari Therapeutics, Plc entered into a definitive agreement to acquire Peak Bio, Inc.. | CI |
| 02-16 | Peak Bio, Inc. announced that it has received $2.238 million in funding | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 |
|---|---|---|
| Capitalization 1 | - | 84.05 |
| Enterprise Value (EV) 1 | - | 91.88 |
| P/E ratio | - | -5.67 x |
| Yield | - | - |
| Capitalization / Revenue | - | 138,304,564 x |
| EV / Revenue | - | 151,191,556 x |
| EV / EBITDA | - | -7.86 x |
| EV / FCF | - | -22,840,848 x |
| FCF Yield | - | -0% |
| Price to Book | - | -10.2 x |
| Nbr of stocks (in thousands) | - | 20,058 |
| Reference price 2 | 9.740 | 4.190 |
| Announcement Date | 17/06/22 | 29/06/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 |
|---|---|---|---|
| Net sales | - | 0.5283 | 0.6077 |
| EBITDA 1 | -13.18 | -8.889 | -11.7 |
| EBIT 1 | -13.34 | -9.066 | -11.85 |
| Operating Margin | - | -1,715.95% | -1,949.68% |
| Earnings before Tax (EBT) 1 | -13.34 | -8.211 | -13.16 |
| Net income 1 | -13.35 | -8.293 | -13.09 |
| Net margin | - | -1,569.65% | -2,153.88% |
| EPS | - | - | -0.7390 |
| Free Cash Flow | - | -5.694 | -4.022 |
| FCF margin | - | -1,077.86% | -661.93% |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 17/06/22 | 17/06/22 | 29/06/23 |
1USD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q2 | 2022 Q3 |
|---|---|---|
| Net sales 1 | 0.1009 | 0.1921 |
| EBITDA | - | - |
| EBIT 1 | - | -1.687 |
| Operating Margin | - | -878.05% |
| Earnings before Tax (EBT) 1 | - | -1.756 |
| Net income 1 | -2.523 | -1.714 |
| Net margin | -2,499.86% | -892.1% |
| EPS 2 | - | -0.2100 |
| Dividend per Share | - | - |
| Announcement Date | 04/10/22 | 15/12/22 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 |
|---|---|---|---|
| Net Debt 1 | 0.02 | 1.29 | 7.83 |
| Net Cash position 1 | - | - | - |
| Leverage (Debt/EBITDA) | -0.001358 x | -0.1456 x | -0.6696 x |
| Free Cash Flow | - | -5.69 | -4.02 |
| ROE (net income / shareholders' equity) | - | 656% | 261% |
| ROA (Net income/ Total Assets) | - | -471% | -172% |
| Assets 1 | - | 1.759 | 7.608 |
| Book Value Per Share | - | - | -0.4100 |
| Cash Flow per Share | - | - | 0.0300 |
| Capex 1 | 0.34 | 0.01 | 0.14 |
| Capex / Sales | - | 1.87% | 23.41% |
| Announcement Date | 17/06/22 | 17/06/22 | 29/06/23 |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -95.41% | 195K | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B | |
| -6.26% | 11.42B |
- Stock Market
- Equities
- PKBO Stock
- Financials Peak Bio, Inc.
